Iksuda Therapeutics procures $47m
Iksuda Therapeutics, a developer of a new generation of antibody drug conjugates, has raised $47 million in funding.
Iksuda Therapeutics, a developer of a new generation of antibody drug conjugates, has raised $47 million in funding.